Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Interventional × Neomycin × Clear all

Phase

Status

Sponsor Class

OTHER 4 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Interventions

pembrolizumab 841 Carboplatin 782 Paclitaxel 771 Gemcitabine 645 Cisplatin 622 Docetaxel 588 Bevacizumab 500 Pemetrexed 406 Cyclophosphamide 395 Nivolumab 390 Capecitabine 375 Fluorouracil 328 Dexamethasone 322 Rituximab 311 Oxaliplatin 280 Injections 279 atezolizumab 249 Trastuzumab 241 Cetuximab 227 Leucovorin 225 Irinotecan 214 Prednisone 211 130-nm albumin-bound paclitaxel 210 Doxorubicin 209 Ipilimumab 185 Lenalidomide 182 Fulvestrant 177 fludarabine 176 durvalumab 168 venetoclax 164

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02001909 2015-08-13

Effect of Neomycin on the Pharmacokinetics of Regorafenib

Bayer

Phase 1 Completed

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡